Myomo (MYO) AI Stock Analysis

• Market Cap: $38.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.45M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: 93.07%
• EPS Growth: 13.25%
• Country: US
• Employees: 184
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Devices
• EPS (TTM): -0.11
• Shares Outstanding: 37,801,070
• 10 Day Avg. Volume: 1,175,065
• 30 Day Avg. Volume: 1,446,737
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.27
• Enterprise Value/Revenue: 2.13
• Enterprise Value/Gross Profit: 3.07
• Enterprise Value/Ebitda: -10.39
• 1Y Price Target: $4.38
• Price Target Upside: 333.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-0.99% Downside)

Myomo's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates bearish momentum, further weighing down the score. While the earnings call and corporate events provide some positive outlooks, they are not enough to offset the significant financial and market challenges.

Positive Factors

Financial Performance

Revenue was ahead of expectations, with management taking action to improve lead quality and conversion metrics, positioning the company well for future growth.

Market Expansion

A positive Medicare ruling has greatly expanded the market for Myomo's products, opening up significant opportunities.

Product Positioning

The MyoPro product is well-positioned to address a largely untapped market for individuals with upper-arm paralysis.

Negative Factors

Financial Metrics

The company's gross margin dropped to 63% from 67% due to higher material and overhead spending and lower volume.

Patient Pipeline

The number of patients added to Myomo's pipeline was significantly lower than expected, impacting the company’s revenues.

Revenue Guidance

Lower-than-expected 3Q25 revenue guidance and reduced full-year 2025 guidance highlight challenges with lead quality and slower authorizations.

Myomo Business Overview & Revenue Model

Company Description

Myomo, Inc. is a medical technology company that specializes in developing wearable robotic devices designed to restore mobility for individuals with upper limb disabilities. The company primarily operates in the healthcare sector, focusing on rehabilitation and assistive technologies. Myomo's core products include myoelectric orthoses that enable users to control their arm and hand movements through muscle signals, enhancing their ability to perform daily activities and improving their quality of life.

How the Company Makes Money

Myomo generates revenue primarily through the sale of its myoelectric orthoses and related products. The company's revenue model includes direct sales to healthcare providers, hospitals, and rehabilitation facilities, as well as partnerships with insurance companies that provide coverage for its devices. Key revenue streams also include leasing programs and service agreements for ongoing support and maintenance of the devices. Additionally, Myomo collaborates with various healthcare organizations and research institutions, which may lead to funding opportunities and grants that contribute to its earnings.

Myomo Financial Statement Overview

Summary

Myomo is experiencing revenue growth but faces significant profitability and cash flow challenges. The company maintains a moderate leverage position, but negative margins and cash flows indicate operational and financial difficulties that need addressing to improve financial health.

Income Statement

Myomo's income statement shows a consistent increase in revenue, with a TTM revenue growth rate of 5.52%. However, the company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin remains strong at 69.24%, but the negative EBIT and EBITDA margins suggest operational inefficiencies.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.71, indicating manageable leverage. However, the return on equity is negative, highlighting profitability challenges. The equity ratio is not explicitly provided, but the company's equity position appears stable relative to its assets.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating and free cash flows. The free cash flow growth rate is positive, but the operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.76M	32.55M	19.24M	15.56M	13.86M	7.58M
Gross Profit	28.22M	23.19M	13.18M	10.25M	10.31M	4.98M
EBITDA	-8.35M	-5.04M	-7.71M	-10.13M	-9.93M	-11.24M
Net Income	-9.32M	-6.18M	-8.15M	-10.72M	-10.37M	-12.04M
Balance Sheet
Total Assets	38.67M	42.24M	14.58M	10.16M	20.10M	14.71M
Cash, Cash Equivalents and Short-Term Investments	15.48M	24.87M	8.87M	5.35M	15.52M	12.24M
Total Debt	12.43M	8.11M	601.30K	553.91K	735.00K	173.44K
Total Liabilities	21.06M	17.53M	5.59M	3.80M	4.69M	3.14M
Stockholders Equity	17.62M	24.71M	8.99M	6.36M	15.41M	11.57M
Cash Flow
Free Cash Flow	-10.35M	-4.65M	-6.32M	-10.35M	-9.87M	-9.08M
Operating Cash Flow	-9.67M	-3.29M	-6.17M	-10.23M	-9.55M	-9.03M
Investing Cash Flow	-1.18M	259.98K	-2.03M	-310.79K	-326.46K	-45.75K
Financing Cash Flow	19.53M	20.93M	9.71M	376.86K	13.17M	16.78M

Myomo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYO, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.72, and below the 200-day MA of 4.13, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 25.98 is Positive, neither overbought nor oversold. The STOCH value of 16.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYO.

Myomo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	74 Outperform	$295.22M	55.03	9.70%	―	27.22%	695.07%
SGHT	55 Neutral	$195.33M	―	-57.10%	―	-3.89%	9.68%
CVRX	52 Neutral	$202.15M	―	-92.33%	―	23.11%	18.06%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
OM	50 Neutral	$243.82M	―	-87.65%	―	2.47%	56.93%
TLSI	47 Neutral	$257.32M	―	271.41%	―	45.50%	53.07%
MYO	44 Neutral	$38.18M	―	-68.32%	―	93.07%	13.25%

Myomo Corporate Events

Myomo Hosts Investor & Analyst Day for Growth

On June 18, 2025, Myomo, Inc. hosted an Investor & Analyst Day, providing an in-depth overview of its business model and long-term financial aspirations. The event highlighted the company’s efforts to improve lead generation, Medicare Advantage reimbursement, and manufacturing capacity. Management shared plans to enhance products and increase production, aiming for $100 million in annual revenue by 2028. The event also showcased Myomo’s commitment to expanding its market presence and improving patient outcomes through innovative medical robotics solutions.

Myomo Holds Annual Stockholders Meeting, Elects New Director

On June 11, 2025, Myomo, Inc. held its Annual Meeting of Stockholders where key decisions were made regarding the company’s governance and financial oversight. The stockholders approved the election of Heather Getz as a Class II director for a three-year term and ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.